|
???tair.name??? >
???browser.page.title.author???
|
"feng y h"???jsp.browse.items-by-author.description???
Showing items 1-10 of 27 (3 Page(s) Totally) 1 2 3 > >> View [10|25|50] records per page
臺大學術典藏 |
2022-08-12T06:27:35Z |
EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid
|
Yeh D.-C.; Chen D.-R.; Chao T.-Y.; Chen S.-C.; Wang H.-C.; Rau K.-M.; Feng Y.-H.; Chang Y.-C.; Lee K.-D.; Ou-Yang F.; Kuo W.-H.; KING-JEN CHANG; Lin Y.-C.; Tseng L.-M.; Hou M.-F. |
臺大學術典藏 |
2022-03-10T06:14:59Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F. |
臺大學術典藏 |
2022-02-21T02:04:35Z |
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study
|
Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG |
國立成功大學 |
2022 |
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
|
Chen, Chen C.-T.;Feng, Y.-H.;Yen, C.-J.;Chen, S.-C.;Lin, Y.-T.;Lu, Lu L.-C.;Hsu, C.-H.;Cheng, A.-L.;Shao, Y.-Y. |
國立成功大學 |
2022 |
An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline
|
Chang, W.-T.;Liu, C.-F.;Feng, Y.-H.;Liao, C.-T.;Wang, J.-J.;Chen, Z.-C.;Lee, H.-C.;Shih, J.-Y. |
國立成功大學 |
2022 |
Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities
|
Wu, N.-C.;Feng, Y.-H.;Kuo, Y.H.;Chen, W.-Y.;Wu, H.-C.;Huang, C.-T.;Wang, Wang W.-C.;Kang, N.-W.;Shih, J.-Y.;Chen, Z.-C.;Chang, W.-T. |
國立成功大學 |
2022 |
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
|
Shao, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Yang, T.-S.;Shen, Y.-C.;Chao, Y.;Chen, J.-S.;Su, C.-Y.;Chen, W.-J.;Hsiang, Hsiang H.-L.;Hsu, C.-H. |
國立成功大學 |
2022 |
The impact of COVID-19 on cardio-oncology care in Taiwan
|
Kang, N.-W.;Feng, Y.-H.;Chen, Z.-C.;Chang, W.-T. |
臺大學術典藏 |
2021-12-01T06:03:00Z |
Treatment outcomes in patients receiving conventional amphotericin B therapy: A prospective multicentre study in Taiwan
|
Chen C.-Y.; Kumar R.N.; Feng Y.-H.; Ho C.-H.; You J.-Y.; Liao C.-C.; Tseng C.-H.; Mavros P.; Gerth W.C.; YEE-CHUN CHEN |
臺大學術典藏 |
2021-08-31T06:29:28Z |
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma
|
Yen C.-J.; Kim T.-Y.; Feng Y.-H.; Chao Y.; Lin D.-Y.; Ryoo B.-Y.; Huang D.C.-L.; Schnell D.; Hocke J.; Loemb? A.-B.; ANN-LII CHENG |
Showing items 1-10 of 27 (3 Page(s) Totally) 1 2 3 > >> View [10|25|50] records per page
|